Did You Know...
...that in the early 1940s GE engineer James Wright was charged with a task of utmost importance to the war effort: develop a cheap substitute for rubber that could be used to produce tires, gas masks and a whole host of military gear. Wright tackled the task diligently -- and wound up inventing Silly Putty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7255854 | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. ... | 08/14/2007 |
| 7173046 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention ... | 02/06/2007 |
| 7112665 | Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants The invention relates to a DNA fragment containing a determined gene, the expression of which inhibits the antibiotic and herbicidal effects of Bialaphos and related products. It also relates to recombinant vectors, containing such DNA fragment, which enable ... | 09/26/2006 |
| 7030080 | Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between... | 04/18/2006 |
| 6962978 | Polymer conjugates of interferon beta-1a and uses An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relativ... | 11/08/2005 |
| 6875743 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them fo... | 04/05/2005 |
| 6861509 | Antibodies to Ret and RetL3 Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients. ... | 03/01/2005 |
| 6835557 | DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human interferon, the genes coding for these polypeptides and methods of making and using these molecules, hosts,... | 12/28/2004 |
| 6800735 | Interferon-beta fusion proteins and uses A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptid... | 10/05/2004 |
| 6696423 | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo an... | 02/24/2004 |
| 6686350 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 02/03/2004 |
| 6677135 | Ret ligand (RetL) for stimulating neutral and renal growth Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients. Isolated nucleic acid and amino acid sequences for Ret ... | 01/13/2004 |
| 6669941 | Soluble lymphotoxin-ଲ receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease This invention relates to compositions and methods comprising "lymphotoxin-ଲ receptor blocking agents", which block lymphotoxin-ଲ receptor signalling. Lymphotoxin-ଲ receptor blocking agents are useful for treating lymphocyte-mediated imm... | 12/30/2003 |
| 6664385 | Kidney injury-related molecules Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.... | 12/16/2003 |
| 6652856 | Method for the treatment of fibrosis Disclosed is a method of treating fibrosis in a human or animal subject. The method comprises administering to the subject an effective amount of an antibody to an integrin or fragment thereof.... | 11/25/2003 |
| 6649600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of n... | 11/18/2003 |
| 6630503 | Cell adhesion inhibitors A cell adhesion inhibitor of the general formula: is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, ... | 10/07/2003 |
| 6630512 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 10/07/2003 |
| 6627202 | HBV core antigen particles with multiple immunogenic components attached via peptide ligands This invention relates to hepatitis B virus ("HBV") core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV cote antigen particles comprising immunogens, epitopes, or other related... | 09/30/2003 |
| 6624152 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 09/23/2003 |
| 6605601 | A1 adenosine receptor antagonists Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condit... | 08/12/2003 |
| 6602503 | Recombinant anti-VLA-4 antibody molecules The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflamma... | 08/05/2003 |
| 6596687 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 07/22/2003 |
| 6552216 | Molecular model for VLA-4 inhibitors Pharmacophore models of VLA-4 inhibitors, methods of identifying novel inhibitors and novel inhibitors identified by these methods.... | 04/22/2003 |
| 6544520 | Hepatitis B virus inhibitors Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them.... | 04/08/2003 |
| 6495525 | VLA-4 inhibitor: oMePUPA-V OMePUPA-V, (R)-N-[[4-[[(2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl-3- methyl)-ଲ-Alanine, a cell adhesion inhibitor, pharmaceutical compositions, and methods of treatment of cell-adhesion mediated pathologies.... | 12/17/2002 |
| 6482409 | Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of a VCAM-1/IgG fusion protein.... | 11/19/2002 |
| 6444793 | Hydrophobically-modified hedgehog protein compositions and methods Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized ... | 09/03/2002 |
| 6429303 | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same An isolated BLAA polynucleotide and the membrane-associated or secreted polypeptide encoded by the BLAA polynucleotide are disclosed. Also disclosed are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant o... | 08/06/2002 |
| 6423824 | CAIP-like gene family CAIP polypeptide, nucleic acid, and uses thereof.... | 07/23/2002 |
| 6403087 | Soluble lymphotoxin-ଲ receptors as therapeutic agents for the treatment of immunological disease This invention relates to compositions and methods comprising "lymphotoxin-ଲ receptor blocking agents", which block lymphotoxin-ଲ receptor signalling. Lymphotoxin-ଲ receptor blocking agents are useful for treating lymphocyte-mediated imm... | 06/11/2002 |
| 6376538 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 04/23/2002 |
| 6338953 | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein Disclosed are methods, nucleic acids, and cells for expressing an exogenous gene in a mammalian cell, involving introducing into the cell a non-mammalian DNA virus (e.g., a baculovirus) having an altered coat protein, the genome of which virus carries an ... | 01/15/2002 |
| 6326183 | Chromatographically concentrated baculovirus and methods A protocol for the ion exchange concentration of baculovirus is presented.... | 12/04/2001 |
| 6323027 | Common gamma chain monoclonal antibody blocking agents The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients wit... | 11/27/2001 |
| 6316003 | Tat-derived transport polypeptides This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomp... | 11/13/2001 |
| 6307025 | VCAM fusion proteins and DNA coding therefor VCAM fusion proteins capable of binding to VLA4, and DNA molecules coding on these fusions.... | 10/23/2001 |
| 6306840 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 10/23/2001 |
| 6297355 | Polypeptides displaying HBV antigenicity or hbv antigen specificity Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV antigenicity and genes coding therefor and methods of making and using these molecules, hosts, genes and polypeptides. The recombinant DNA molecules of thi... | 10/02/2001 |
| 6270955 | Pharmaceutical compositions and methods for producing antibodies to hepatitis b virus and kits and methods for detecting antibodies to hepatitis b virus Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV anti-genicity and genes coding therefor and methods of making and using these molecules, hosts, genes and polypeptides. The recombinant DNA molecules of th... | 08/07/2001 |
